UPDATE - New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS
September 22 2021 - 6:33PM
Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from neurohealth disorders announced today that a peer-reviewed
paper showed significantly lower seizure risk with NeuroStar®
Advanced Therapy for Mental Health than with TMS treatments that
claim deeper stimulation with H-Coil technology. The paper, titled
“Seizure risk with repetitive TMS: Survey results from over a
half-million treatment sessions” published in Brain Stimulation,
the premier journal for publication of original research in the
field of neuromodulation, electronically surveyed all of the
approximately 500 members of the Clinical TMS Society (CTMSS) about
seizures in their practice.
“While the overall occurrence of seizures with all TMS
treatments is low, this study showed that the real-world risk for
seizure was 52 to 90 times higher with H-coil TMS treatment than
with NeuroStar treatment,” stated Cory Anderson, VP, Clinical
Affairs & Interim VP, R&D, Neuronetics. “From NeuroStar’s
Figure-8 coil design, to being backed by the largest clinical data
set of any TMS treatment for depression, to our comprehensive
training programs, Neuronetics always aspires to provide the safest
and most efficacious treatment for our providers and their
patients.”
One-hundred thirty-four surveys were returned and nine were
excluded due to data inconsistencies, leaving a total of 125
surveys to evaluate which included 586,656 TMS treatment sessions.
To distinguish seizures from non-seizures, a Board-certified
neurologist conducted remote interviews. The survey respondents
included a wide range of clinical practices, and provided a way to
estimate TMS seizure risk under real-world practice conditions. The
resulting data provide the largest real-world sample size
estimation of TMS seizure risk across device manufacturers. The
authors hypothesized that the higher risk of seizure with the
H-Coil design was due, in part, to the broader and less focused
stimulation field which may stimulate unintended regions of the
brain and lead to seizures.
“One of the reasons I chose NeuroStar for my practice is the
precision of the treatment,” said Kenneth Pages, MD, TMS of South
Tampa. “Precision is a critical component of TMS dosing and
delivery. I trust NeuroStar’s technology with Contact Sensing to
give me peace of mind that my patients are receiving the treatment
dose I’ve prescribed, without treating areas of the brain that are
unrelated to their depression.”
To learn more about NeuroStar® Advanced Therapy, visit
www.neurostar.com.
About NeuroneticsNeuronetics, Inc. believes
that mental health is as important as physical health. As a global
leader in neuroscience and the largest TMS company in the industry,
Neuronetics is redefining patient and physician expectations by
designing and developing products that improve the quality of life
for people suffering from neurohealth conditions. An FDA-cleared,
non-drug, noninvasive treatment for people with depression,
Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading
transcranial magnetic stimulation (TMS) treatment for major
depressive disorder in adults with over four million treatments
delivered. NeuroStar is widely researched and backed by the largest
clinical data set of any TMS system for depression, including the
world’s largest depression Outcomes Registry. Neuronetics is
committed to transforming lives by offering an exceptional
treatment option that produces extraordinary results. For safety
information and indications for use, visit NeuroStar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2023 to Apr 2024